Legend Biotech 2 Adr Rep logo

Legend Biotech 2 Adr Rep

Stock
Stock
Ticker: LEGN
LEGN

Price

Price

CHART BY

Frequently asked questions

The market capitalization of Legend Biotech 2 Adr Rep is $3.61B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
Legend Biotech 2 Adr Rep's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.499. EPS indicates the company's profitability on a per-share basis.
Currently, 18 analysts cover Legend Biotech 2 Adr Rep's stock, with a consensus target price of $46.89. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Legend Biotech 2 Adr Rep reported a revenue of $1.27B.
Legend Biotech 2 Adr Rep's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$6.97M. EBITDA measures the company's overall financial performance.
Legend Biotech 2 Adr Rep has a free cash flow of -$264.16M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Legend Biotech 2 Adr Rep employs approximately 2,900 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
The free float of Legend Biotech 2 Adr Rep is 184.80M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$3.61B
EPS (TTM) 
-$0.499
Free Float 
184.80M
Revenue (TTM) 
$1.27B
EBITDA (TTM) 
-$6.97M
Free Cashflow (TTM) 
-$264.16M

Pricing

1D span
$18.20$18.50
52W span
$16.25$37.29

Analyst Ratings

The price target is $46.89 and the stock is covered by 18 analysts.

Buy

12

Hold

6

Sell

0

Information

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Employees
2,900
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

Primary Ticker
LEGN

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation